A parade of politicians, physicians and pundits have criticized a Super Bowl commercial intended to stimulate awareness of opioid-induced constipation, linking the campaign to the opioid prescription drug addiction problem in the U.S. and forcing AstraZeneca and Daiichi Sankyo, which market the OIC relief drug Movantik, to defend it.
Tokyo-based Daiichi Sankyo said it would join with a mix of foreign multinationals and Japanese companies in sharing clinical trial data with qualified researchers.
In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. Now, here's the full list of new drugs approved by the FDA in 2015, in chronological order.
Daiichi Sankyo is closing up its German research outpost, shuttering the former U3 Pharma as it consolidates its global R&D presence.
It's been rough lately for Daiichi Sankyo, and now, things are going from bad to worse. The beleaguered Japanese drugmaker is shuttering its German antibody subsidiary, months after it announced that it would cut half its U.S. workforce in a bid to revive business and prepare for the patent loss for its best-selling drug.
In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.
The U.S. Supreme Court dealt a blow to Daiichi Sankyo and Mylan Pharmaceuticals when the court declined to hear their appeal in their attempt to head off drugmaker Apotex from introducing a generic version of the hypertension drug Benicar.
Japan's Daiichi Sankyo and its associated company Plexxikon said the U.S. Food and Drug Administration (FDA) has approved cobimetinib for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), the company said in a statement.
As if Daiichi Sankyo didn't have trouble enough, the struggling Japanese drugmaker, which is laying off thousands of employees to cut costs, is again having issues with its vaccine production.
Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it moves toward approval.